Every Form 4 that Nuvalent, Inc. (NUVL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NUVL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NUVL filings page.
Deerfield-affiliated reporting persons for Nuvalent, Inc. disposed of all indirectly held Class A and Class B common stock, RSUs and stock options in connection with Nuvalent’s cash acquisition by GlaxoSmithKline. Each share was cancelled or tendered for $124.00 in cash, leaving all reported Nuvalent equity positions at zero.
Nuvalent, Inc. director Michael L. Meyers reported disposing of his Nuvalent equity in connection with its acquisition by GlaxoSmithKline affiliates. A tender offer purchased 5,146.0000 shares of Class A common stock at $124.00 per share, followed by a merger that made Nuvalent a wholly owned subsidiary of GlaxoSmithKline LLC.
In the same transaction, 3,444.0000 restricted stock units and multiple stock option grants covering 4,147.0000, 3,789.0000, 15,000.0000, 40,000.0000 and 8,361.0000 underlying shares were cancelled and converted into rights to receive cash based on the $124.00 offer price. The Form 4 shows 0.0000 holdings remaining in these reported securities after the transactions.
Nuvalent, Inc. Chief Financial Officer Alexandra Balcom reported transactions tied to the closing of a merger with a GlaxoSmithKline affiliate. She tendered 44,433 shares of Class A common stock for $124.00 per share in cash pursuant to a tender offer. In connection with the merger, 41,100 restricted stock units and multiple tranches of stock options were cancelled and converted into cash based on the $124.00 offer price and each option’s exercise price. Performance stock units totaling 14,350 shares, including 5,600 granted in 2025 and 8,750 granted in 2026, vested under the merger terms.
Nuvalent, Inc. director Sapna Srivastava reported dispositions of equity tied to the cash tender offer and merger with a GlaxoSmithKline affiliate. She tendered 5,146 shares of Class A Common Stock at $124.00 per share and had 3,444 restricted stock units plus several stock option grants cancelled and converted into cash rights under the Merger Agreement, leaving the reported positions in these securities at zero.
Nuvalent, Inc. director Christy J. Oliger reported disposing of equity awards in connection with the GlaxoSmithKline transaction. She tendered 1,324 Class A shares in the offer at $124.00 per share and had 6,091 time-based RSUs and 6,119 stock options canceled and converted into cash rights under the Merger Agreement, leaving no holdings in these awards.
Nuvalent, Inc. director Ron Squarer reported issuer dispositions of equity awards in connection with Nuvalent’s acquisition by a subsidiary of GlaxoSmithKline LLC. Following a $124.00-per-share cash tender offer and subsequent merger, 6,281 time-based restricted stock units and stock options for 4,418 shares at a $105.74 exercise price were canceled and converted into rights to receive cash, leaving no reported holdings of these awards.
Turner Christopher Durant, Chief Medical Officer of Nuvalent, Inc., reported multiple equity award and share dispositions tied to GlaxoSmithKline LLC’s acquisition of Nuvalent under a June 9, 2026 Agreement and Plan of Merger.
He tendered 31,530 Class A shares at $124.00 per share. In addition, 41,100 RSUs and 14,350 PSUs were cancelled and converted into cash based on the $124.00 offer price, and several stock option grants (including 144,200 options at $27.85 and 107,000 at $18.93) were cancelled for cash equal to the excess of the offer price over their exercise prices.
Nuvalent, Inc. Chief Development Officer Darlene Noci reported merger-related equity transactions tied to a GlaxoSmithKline affiliate’s tender offer and subsequent merger. She tendered 17,017 shares of Class A Common Stock at $124.00 per share, while her restricted stock units, performance stock units and stock options were cancelled and converted into the right to receive cash based on the Offer Price under the Merger Agreement. A total of 14,350 performance stock units vested in connection with the merger, and the reported awards and options show zero remaining balances after these transactions.
Nuvalent, Inc. officer Lane Benjamin reported transactions tied to the closing of a merger with a GlaxoSmithKline affiliate. He tendered 21,092 shares of Class A Common Stock in a cash tender offer at $124.00 per share. Equity awards, including 29,433 RSUs, 7,120 PSUs and multiple stock option grants, were cancelled and converted into cash-settled rights based on the Offer Price under the Merger Agreement.
Nuvalent, Inc. Chief Scientific Officer Henry E. Pelish reported multiple equity dispositions tied to the company’s change of control. He tendered 22,393 Class A common shares at $124.00 per share in a completed tender offer by a GlaxoSmithKline LLC affiliate.
Pursuant to the merger agreement, his time-based restricted stock units and performance stock units, as well as several stock option grants with various exercise prices, were cancelled and converted into cash based on the same $124.00 Offer Price, less applicable withholding taxes.
Nuvalent, Inc. President and CEO James Richard Porter reported equity transactions tied to a tender offer and subsequent merger with an affiliate of GSK plc. He tendered 203,529 Class A shares at $124.00 per share in cash. All reported RSUs, PSUs and stock options were canceled and converted into cash rights based on this Offer Price, with post-transaction holdings shown as 0 for all listed Nuvalent equity securities.
Nuvalent, Inc. Chief Legal Officer Deborah Ann Miller reported cash-settling her equity in connection with Nuvalent’s acquisition by a GlaxoSmithKline affiliate. She tendered 18534 Class A shares at $124.00 per share and had PSUs, RSUs and several stock option grants canceled for cash under a June 9, 2026 Merger Agreement.
Nuvalent, Inc. director Anna Protopapas reported dispositions of equity awards and shares on 2026-07-15 in connection with a change of control. A GlaxoSmithKline LLC subsidiary completed a tender offer to purchase all outstanding Nuvalent Class A and Class B Common Stock for $124.00 per share in cash, followed by a merger in which Nuvalent became a wholly owned subsidiary of GlaxoSmithKline LLC.
Protopapas tendered 5,146 shares of Class A Common Stock at the $124.00 Offer Price and disposed of 3,444 restricted stock units, which were canceled and converted into a cash right based on the Offer Price. Several stock option grants covering 4,147, 3,789, 15,000, 15,000 and 40,000 underlying shares, with exercise prices between $9.36 and $80.03 per share, were also canceled and converted into cash rights calculated under the Merger Agreement. Following these transactions, her reported holdings in these securities were reduced to zero.
Nuvalent, Inc. director Grant C. Bogle reported the cash-out of his equity in connection with the company’s acquisition by an affiliate of GlaxoSmithKline. A tender offer purchased outstanding Nuvalent shares at $124.00 per share, followed by a merger that made Nuvalent a wholly owned subsidiary of the buyer.
Bogle disposed of 3,714 shares of Class A Common Stock pursuant to the tender offer at $124.00 per share. In addition, 5,577 restricted stock units were cancelled and converted into a cash right equal to the Offer Price per underlying share. Two stock option awards covering 4,147 shares at $75.5300 and 4,851 shares at $93.7300 were also cancelled and converted into cash based on the excess of the $124.00 Offer Price over their exercise prices. Following these transactions, the reported holdings for these securities are 0 shares.
Nuvalent, Inc. director Wheeler Cameron, a partner in Deerfield Management Company, reported merger-related dispositions in connection with GlaxoSmithKline’s tender offer and subsequent merger. An account he holds for the benefit, and at the direction, of Deerfield tendered 5,146 Class A shares at $124.00 per share, while 3,444 RSUs and several stock option grants were cancelled and converted into cash rights based on the $124.00 offer price and the options’ exercise prices. Cameron has no pecuniary interest in these securities, disclaims beneficial ownership, and the reported holdings in these instruments fell to zero.
Nuvalent, Inc. Chief Scientific Officer Henry E. Pelish reported an open-market sale of 2,111 shares of Class A common stock at $123.81 per share on July 9, 2026. The transaction was executed pursuant to a durable Rule 10b5-1 sell-to-cover instruction to satisfy tax withholding obligations upon vesting of previously granted equity awards. Following this transaction, Pelish directly holds 63,493 shares of Nuvalent Class A common stock.
Nuvalent, Inc. President and CEO James Richard Porter executed a pre-planned option exercise and related share sale. He exercised stock options covering 30,000 shares of Class A Common Stock at $18.93 per share and sold 30,000 shares in open-market transactions at a weighted average price of $123.72 per share.
The filing states these trades were carried out under a Rule 10b5-1 trading plan adopted on December 4, 2025, indicating they were scheduled in advance. Following the transactions, Porter directly holds 324,879 shares of Class A Common Stock. The options exercised were fully vested and no remaining derivative holdings are shown in this filing.
Nuvalent, Inc.’s Chief Development Officer Darlene Noci exercised stock options and sold shares of Class A Common Stock. On July 1, 2026, she exercised options for a total of 23,000 shares at exercise prices of $72.35 and $18.93 per share, then sold 23,000 shares in an open-market transaction at a weighted average price of $123.59 per share. After these transactions, she directly owned 58,117 shares of Class A Common Stock. The filing notes the transactions were executed under a Rule 10b5-1 trading plan adopted on November 18, 2024.
Nuvalent, Inc. Chief Financial Officer Alexandra Balcom exercised stock options and sold shares of Class A Common Stock. She exercised options to acquire 6,046 shares at $18.93 per share and 5,384 shares at $6.89 per share, then sold 11,430 shares in an open-market transaction at a weighted average price of $123.58 per share. These trades were executed under a Rule 10b5-1 trading plan adopted on December 23, 2025. Following the sale, she directly holds 85,533 shares of Class A Common Stock and retains stock options covering 22,933 and 8,016 shares with exercise prices of $18.93 and $6.89, respectively.
Nuvalent, Inc. Chief Development Officer Darlene Noci reported an exercise-and-sell transaction in Class A Common Stock. She exercised stock options to acquire 5,500 shares at $27.85 per share and sold 5,500 shares in open-market trades at a weighted average price of $123.51 per share.
The filing shows these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2024. After the sale, she directly held 58,117 shares of Nuvalent Class A Common Stock.
Flynn James E reported acquisition or exercise transactions in this Form 4 filing.
Nuvalent, Inc. reported an updated insider position for entities affiliated with Deerfield Management Company, L.P., highlighting a new equity award tied to board service. On June 16, 2026, 3,444 restricted stock units (RSUs) were granted to director Cameron Wheeler, which are held for the benefit and at the direction of Deerfield Management.
Each RSU represents one share of Nuvalent Class A common stock and vests in full on the earlier of June 16, 2027 or the company’s next annual stockholder meeting, subject to Wheeler’s continued service. The filing also lists indirect Class A common stock holdings through several Deerfield funds, including 8,299,225 shares through Deerfield Healthcare Innovations Fund, L.P., 650,000 shares through Deerfield Partners, L.P., and 10,292 shares through Deerfield Management Company, L.P. The reporting persons disclaim beneficial ownership except to the extent of any indirect pecuniary interest.
Wheeler Cameron reported acquisition or exercise transactions in this Form 4 filing.
Nuvalent, Inc. reported that 3,444 shares of its Class A Common Stock were awarded in the form of restricted stock units to director Cameron Wheeler. The award was granted at no cash cost per share and brings the reported holding to 8,590 RSUs.
According to the disclosure, Wheeler is a partner in Deerfield Management Company, L.P., has no pecuniary interest in these securities, and holds them for the benefit and at the direction of Deerfield. The RSUs vest in full on the earlier of June 16, 2027 or Nuvalent’s next annual stockholder meeting, subject to continued service.
Srivastava Sapna reported acquisition or exercise transactions in this Form 4 filing.
Nuvalent, Inc. director Sapna Srivastava received an equity award of 3,444 restricted stock units (RSUs) of Class A Common Stock. Each RSU represents the right to receive one share of Nuvalent Class A Common Stock. The RSUs vest in full on the earlier of June 16, 2027 or the company’s next annual meeting of stockholders, subject to her continued service. Following this grant, she holds 8,590 shares of Class A Common Stock directly.
Squarer Ron reported acquisition or exercise transactions in this Form 4 filing.
Nuvalent, Inc. director Ron Squarer reported an equity award of Class A Common Stock in the form of restricted stock units. He received 3,444 RSUs, each convertible into one share of Class A Common Stock at no purchase price.
The RSUs vest in full on the earlier of June 16, 2027 or the date of Nuvalent’s next annual meeting of stockholders, as long as Squarer continues to provide service through that date. After this grant, his reported direct holdings total 6,281 shares.
Protopapas Anna reported acquisition or exercise transactions in this Form 4 filing.
Nuvalent, Inc. director Anna Protopapas reported an equity award of 3,444 restricted stock units (RSUs) of Class A Common Stock. The award was recorded at a price of $0.00 per share, reflecting a compensation grant rather than a market purchase or sale.
Each RSU represents the right to receive one share of Nuvalent Class A Common Stock. The RSUs vest in full on the earlier of June 16, 2027 or the date of Nuvalent's next annual meeting of stockholders, subject to her continued service through the vesting date. Following this grant, she holds 8,590 shares directly.
Oliger Christy J. reported acquisition or exercise transactions in this Form 4 filing.
Nuvalent, Inc. director Christy J. Oliger reported a compensation-related equity award of 3,444 shares of Class A Common Stock in the form of restricted stock units (RSUs). These RSUs vest in full on the earlier of June 16, 2027 or Nuvalent’s next annual stockholder meeting, subject to continued service. Following this grant, Oliger reports 7,415 shares of Class A Common Stock, including these RSUs, held directly.
Nuvalent, Inc. director Michael L. Meyers reported an equity grant of 3,444 shares of Class A Common Stock through restricted stock units (RSUs) at no cash cost. Each RSU converts into one share and vests in full on the earlier of June 16, 2027 or Nuvalent’s next annual stockholder meeting, subject to his continued service. Following this award, he holds 8,590 shares directly.
Bogle Grant C. reported acquisition or exercise transactions in this Form 4 filing.
Nuvalent, Inc. director Grant C. Bogle received an equity award of 3,444 restricted stock units (RSUs) of Class A Common Stock. Each RSU represents one share of Class A Common Stock granted at $0.00 per share as compensation, not a market purchase.
The RSUs vest in full on the earlier of June 16, 2027 or Nuvalent’s next annual meeting of stockholders, as long as Bogle continues providing service through that date. After this award, Bogle’s direct holdings reported in this filing total 9,291 shares, including the RSUs.
Nuvalent, Inc. Chief Development Officer Darlene Noci reported option exercises and a share sale. On June 9, 2026, she exercised stock options for 20,000 shares of Class A Common Stock at exercise prices of $18.93, $6.89, and $1.08 per share.
On the same date, she sold 20,000 shares in an open-market transaction at an average price of $122.81 per share pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2024. Following these transactions, she directly held 58,117 shares of Class A Common Stock.
Nuvalent, Inc. President and CEO James Richard Porter reported an exercise-and-sell transaction involving Class A Common Stock. On June 8, 2026, he sold a total of 30,000 shares in open-market sales at weighted average prices in the high-$80 range, pursuant to a Rule 10b5-1 trading plan adopted on December 4, 2025. On the same date, he exercised stock options for 30,000 shares at an exercise price of $18.93 per share. Following these transactions, he directly holds 324,879 shares of Nuvalent Class A Common Stock and 148,686 stock options with a stated exercise price of $18.93 per share and expiration in 2032.
Nuvalent, Inc. Chief Financial Officer Alexandra Balcom reported a mix of stock sales and an option exercise in Class A Common Stock. On June 1, 2026, she sold a total of 11,430 shares in multiple open-market transactions at weighted average prices within ranges from $94.48 to $104.19 per share under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025.
On the same date, she exercised stock options to acquire 11,430 shares at an exercise price of $6.89 per share. Following these transactions, Balcom directly owned 85,533 shares of Nuvalent Class A Common Stock, indicating she retained a substantial equity position after the activity.
Nuvalent, Inc.’s Chief Development Officer, Darlene Noci, reported a combination of option exercise and share sales in Class A Common Stock. On May 28, 2026, she exercised stock options to acquire 5,500 shares at an exercise price of $27.85 per share and sold 5,500 shares in open-market transactions.
The sales occurred in multiple trades at reported weighted average prices including $109.76, $109.30, $108.01, $107.33, and $106.26 per share. According to a footnote, these transactions were carried out under a Rule 10b5-1 trading plan adopted on November 18, 2024, indicating they were pre-arranged rather than timed discretionarily.
Nuvalent, Inc.’s Chief Legal Officer Deborah Ann Miller reported an exercise-and-sell transaction involving 5,500 shares of Class A Common Stock. On May 28, 2026, she exercised stock options for 5,500 shares at an exercise price of $6.89 per share and sold 5,500 shares in multiple open-market trades at weighted average prices between approximately $105.87 and $109.76 per share pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2024.
Following these transactions, she directly holds 59,634 shares of Nuvalent Class A Common Stock, indicating she retains a substantial equity position while monetizing part of her stake using fully vested options.
Nuvalent, Inc. President and CEO James Richard Porter reported an exercise-and-sell transaction involving the company’s Class A common stock. On May 4, 2026, he exercised stock options to acquire 30,000 shares at $18.93 per share, then sold 30,000 shares in open-market trades.
The sales occurred in multiple transactions at weighted average prices between about $98.28 and $103.05, executed pursuant to a Rule 10b5-1 trading plan adopted on December 4, 2025. Following these transactions, Porter directly holds 354,879 shares of Class A common stock and 178,686 stock options expiring on January 4, 2032.
Nuvalent, Inc. Chief Financial Officer Alexandra Balcom reported a mix of stock option exercises and share sales in Class A common stock. On May 1, 2026, she exercised options to acquire a total of 11,430 shares through two transactions at exercise prices of $6.89 and $1.08 per share.
On the same date, Balcom sold an aggregate of 11,430 shares in open-market transactions at weighted average prices of about $98–$100 per share, with individual sale prices ranging from $97.84 to $100.36. The filing notes these trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025, indicating the timing of the sales was set in advance.
Nuvalent, Inc. Chief Legal Officer Deborah Ann Miller exercised stock options and sold shares in a planned transaction. On April 30, 2026, she sold 1,082 Class A common shares at a weighted average price of $99.57 and 4,418 shares at a weighted average price of $99.13 in open-market sales.
On the same date, she exercised options to acquire 5,500 Class A common shares at an exercise price of $6.89 per share from a fully vested option grant. After these transactions, she directly holds 59,634 Class A common shares. The sales were made pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2024.
Nuvalent, Inc. Chief Development Officer Darlene Noci reported an exercise-and-sell transaction in Class A Common Stock. On April 29, 2026, she exercised 5,500 stock options at $27.85 per share and sold 5,500 shares in multiple open‑market trades around the $99–$101 range. After these transactions, she directly held 58,117 shares of Class A Common Stock. The filing notes the trades were made under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 18, 2024, indicating the timing was set in advance.
Nuvalent, Inc. Chief Scientific Officer Henry E. Pelish exercised stock options and sold shares in a planned transaction. On April 9, 2026, he exercised options to acquire 3,093 shares of Class A common stock at an exercise price of $27.85 per share.
That same day, he sold 2,193 shares at a weighted average price of $104.27 and 900 shares at a weighted average price of $105.00 under a Rule 10b5-1 trading plan adopted on December 11, 2025. After these transactions, he held 65,604 shares of Class A common stock directly.
Nuvalent, Inc. President and CEO James Richard Porter reported an exercise-and-sell transaction involving company stock. He exercised stock options covering 13,714 shares of Class A Common Stock at an exercise price of $18.93 per share and 16,286 shares at $27.85 per share, acquiring 30,000 shares in total. On the same date, he sold 30,000 shares of Class A Common Stock in open-market transactions at prices reported as $103.21, $103.78, $104.78 and $105.60 per share. According to a footnote, these sales were made pursuant to a Rule 10b5-1 trading plan adopted on December 4, 2025. Following the transactions, he directly held 324,879 shares of Nuvalent Class A Common Stock.
Nuvalent, Inc. Chief Financial Officer Alexandra Balcom exercised stock options for 11,430 shares of Class A common stock at an exercise price of $1.08 per share. On the same date, she sold 11,430 shares in open-market transactions at weighted average prices between $103.81 and $106.69.
The filing shows these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025, indicating the sales were scheduled in advance. Following the transactions, Balcom directly holds 85,533 shares of Nuvalent Class A common stock.
Nuvalent, Inc. reported that officer Benjamin Lane received new equity-based compensation. On April 1, 2026, Lane was granted a stock option for 19,000 shares of Class A common stock at an exercise price of $105.64 per share, expiring in 2036. He also received 9,500 shares of Class A common stock in the form of restricted stock units, which vest in three equal annual installments starting after April 1, 2026, subject to continued service. Following the RSU grant, Lane directly holds 50,368 shares of Class A common stock.
Nuvalent, Inc. Chief Development Officer Darlene Noci exercised stock options and sold shares in a planned transaction. She exercised options to acquire 5,500 shares of Class A Common Stock at $27.85 per share, then sold 5,500 shares in two open-market trades at weighted average prices of $97.43 and $98.13, all under a Rule 10b5-1 trading plan adopted on November 18, 2024. After these transactions, she directly holds 58,117 shares of Class A Common Stock and 97,829 option shares, indicating she retains a substantial equity stake despite the routine liquidity event.
Nuvalent, Inc. Chief Legal Officer Deborah Ann Miller exercised stock options and sold shares in a planned transaction. She exercised options to acquire 5,500 shares of Class A Common Stock at an exercise price of $6.89 per share, from options that are fully vested. On the same date, she sold a total of 5,500 shares in three open-market trades at weighted average prices around $97.50–$99.46 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2024. After these transactions, she directly holds 59,634 shares of Class A Common Stock and retains 83,608 stock options outstanding, according to the filing.
Nuvalent, Inc. Chief Financial Officer Alexandra Balcom reported an exercise-and-sale set of transactions in company stock. On March 24, 2026, she exercised stock options for 11,430 shares of Class A Common Stock at $1.08 per share and sold 11,430 shares that day in open-market trades at weighted-average prices in the mid-$90s. She then sold an additional 13,700 shares on March 25, 2026 at a weighted-average price of $100.16 per share in open-market transactions. All sales were executed under a Rule 10b5-1 trading plan adopted on December 23, 2025. After these transactions, she directly holds 85,533 shares of Nuvalent Class A Common Stock.
Nuvalent, Inc.’s Chief Scientific Officer Henry E. Pelish exercised stock options and sold shares of Class A Common Stock in mid-March 2026. He exercised options covering 17,320 shares at strike prices between $18.93 and $72.35, converting them into common shares.
On March 12–13, 2026, he then executed open-market sales totaling 35,104 shares at weighted average prices around the high‑$90s, in multiple trades across price ranges from $97.08 to $100.14. These trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025. After these transactions, Pelish directly holds 65,604 shares of Nuvalent Class A Common Stock.
Nuvalent, Inc. President and CEO James Richard Porter exercised stock options for 30,000 shares of Class A common stock at an exercise price of $27.85 per share. These options were part of a grant vesting monthly over four years from January 6, 2023.
On the same date, he sold 30,000 shares of Class A common stock in open-market transactions at weighted average prices of about $98.59, $99.29 and $100.19, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on December 4, 2025. Following these transactions, he directly holds 324,879 shares of Nuvalent Class A common stock.
Nuvalent, Inc.’s Chief Development Officer Darlene Noci reported option exercises and share sales. On February 26, 2026, she exercised stock options for 5,500 shares of Class A common stock and acquired those shares via derivative conversion.
On the same date, she sold a total of 5,500 Class A common shares in open-market transactions at weighted average prices between $102.04 and $104.41 per share, under a Rule 10b5-1 trading plan adopted on November 18, 2024. After these transactions, she held 58,117 Class A common shares directly.
Nuvalent, Inc. Chief Legal Officer Deborah Ann Miller exercised stock options for 5,500 shares of Class A common stock on February 26, 2026, converting a derivative security into common stock at an exercise price of approximately $6.89 per share. On the same date, she sold a total of 5,500 shares of Class A common stock in open-market transactions at weighted average prices ranging from $101.96 to $103.95, pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2024. Following these transactions, she directly held 59,634 shares of Class A common stock and 89,108 derivative securities.
Nuvalent, Inc.’s Chief Development Officer, Darlene Noci, reported an options exercise and related share sales. On January 29, 2026, she exercised 5,500 stock options at $27.85 per share, receiving the same number of Class A common shares.
That same day she sold portions of Class A common stock in several trades: 189 shares at $100.95, 3,429 shares at $101.8, 1,819 shares at $102.67, and 63 shares at $103.39, with prices reported as weighted averages. These transactions were executed under a Rule 10b5-1 trading plan adopted on November 18, 2024.
After the reported transactions, Noci directly held 58,117 shares of Class A common stock and 108,829 stock options. The option underlying the 5,500-share exercise vests in equal monthly installments over four years following January 6, 2023, subject to continued service.
Nuvalent, Inc. Chief Legal Officer Deborah Ann Miller reported option exercises and share sales under a pre-arranged trading plan. On January 21, 2026 she exercised 700 stock options at an exercise price of $27.85 per share and sold 700 shares of Class A common stock at a weighted average price of $109.84 per share, leaving 59,634 shares owned directly. On January 22, 2026 she exercised an additional 14,300 options at $27.85 per share and sold 14,300 shares at a weighted average price of $110.16 per share, again leaving 59,634 shares owned directly. The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2024, and the underlying options vest in equal monthly installments over four years following January 6, 2023, subject to continued service.